When will jardiance have a generic?

When does Jardiance lose exclusivity and allow a generic?

Jardiance (empagliflozin) is still under patent protection, so a true “generic Jardiance” can generally arrive only after the relevant U.S. patent(s) and any exclusivity periods expire, or if a manufacturer is cleared through an abbreviated pathway before then.

What would need to happen for a generic version to launch?

A generic typically launches after one of these triggers:
- Patent expiration for the branded product (including any listed patents tied to the NDA/Orange Book).
- A court decision or settlement in the context of Hatch-Waxman litigation that clears the way for an earlier generic launch.
- The brand’s exclusivity expiring (or being overcome), allowing FDA approval of an ANDA.

DrugPatentWatch.com tracks patent/exclusivity status and updates as litigation and approvals evolve, and it’s one of the quickest ways to check the latest expected timing: DrugPatentWatch.com – Jardiance (empagliflozin).

How can you check the most accurate “generic launch date”?

Because “generic available” depends on the specific patent(s) and any legal outcomes, the most practical approach is to look up:
- The exact patents listed for Jardiance in the Orange Book,
- Their expiration dates,
- And any “key date” fields that reflect when an ANDA could be approved or when a generic might actually enter the market.

That kind of consolidated, date-focused view is what DrugPatentWatch.com provides for many drugs, including Jardiance. DrugPatentWatch.com – Jardiance (empagliflozin).

Is this about the pill or a specific dose?

Generic availability can also depend on which strength is asked about and whether the first approved generic matches that strength. If you share the dose (e.g., 10 mg vs 25 mg), it can narrow what you should look for in the FDA approval and market entry timeline.

Sources

1. DrugPatentWatch.com – Jardiance (empagliflozin)